AriBioLab Co.,Ltd. (KOSDAQ:261780)
South Korea · Delayed Price · Currency is KRW 2,595.00
+130.00 (5.27%)
At close: Sep 3, 2026
AriBioLab Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 173.16 | 158.62 | 370.66 | 294.12 | 179.48 | 500 |
Other Revenue | -0 | -0 | -0 | -0 | -0 | - |
| 173.16 | 158.62 | 370.66 | 294.12 | 179.48 | 500 | |
Revenue Growth | 9.17% | -57.21% | 26.02% | 63.87% | -64.10% | 542.70% |
Cost of Revenue | 13 | 14.7 | 23.93 | 34.5 | 19 | - |
Gross Profit | 160.16 | 143.92 | 346.73 | 259.62 | 160.49 | 500 |
Selling, General & Admin | 1,901 | 1,981 | 1,874 | 2,197 | 2,357 | 3,199 |
Research & Development | 10,813 | 11,978 | 5,678 | 3,949 | 3,855 | 3,140 |
Amortization of Goodwill & Intangibles | 27.57 | 25.75 | 22.58 | 8.54 | 9.14 | 10.76 |
Operating Expenses | 13,133 | 14,415 | 8,043 | 6,679 | 6,630 | 6,585 |
Operating Income | -12,973 | -14,271 | -7,696 | -6,419 | -6,469 | -6,085 |
Interest Expense | -1,753 | -2,152 | -1,288 | -2,631 | -2,567 | -2,122 |
Interest & Investment Income | 580.59 | 950.2 | 1,384 | 2,282 | 1,017 | 179.88 |
Currency Exchange Gain (Loss) | -0.21 | -0.69 | 10.02 | 2.67 | 0.02 | 0.17 |
Other Non Operating Income (Expenses) | 112.76 | -633.21 | -2,891 | 4,703 | 1,198 | -10,520 |
EBT Excluding Unusual Items | -14,033 | -16,107 | -10,481 | -2,063 | -6,821 | -18,546 |
Gain (Loss) on Sale of Investments | 3.07 | 263.18 | 66.77 | -40.4 | 105.84 | 125.77 |
Other Unusual Items | -389.9 | -200.68 | - | - | - | - |
Pretax Income | -14,420 | -16,044 | -10,414 | -2,103 | -6,715 | -18,420 |
Income Tax Expense | - | - | -275.5 | -353.77 | - | - |
Net Income | -14,420 | -16,044 | -10,138 | -1,749 | -6,715 | -18,420 |
Net Income to Common | -14,420 | -16,044 | -10,138 | -1,749 | -6,715 | -18,420 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 27 | 27 | 27 | 27 | 26 | 23 |
Shares Outstanding (Diluted) | 27 | 27 | 27 | 27 | 26 | 23 |
Shares Change | 0.14% | 0.13% | 1.18% | 0.26% | 13.39% | 30.03% |
EPS (Basic) | -536.24 | -597.44 | -378.00 | -66.00 | -254.00 | -790.00 |
EPS (Diluted) | -536.24 | -597.44 | -378.00 | -66.00 | -254.00 | -790.00 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -9,205 | -11,134 | -8,275 | -5,572 | -5,636 | -5,419 |
Free Cash Flow Per Share | -342.30 | -414.59 | -308.52 | -210.20 | -213.18 | -232.41 |
Gross Margin | 92.49% | 90.73% | 93.55% | 88.27% | 89.42% | 100.00% |
Operating Margin | -7491.67% | -8997.23% | -2076.42% | -2182.53% | -3604.36% | -1216.93% |
Profit Margin | -8327.31% | -10115.30% | -2735.23% | -594.82% | -3741.36% | -3684.01% |
Free Cash Flow Margin | -5315.64% | -7019.41% | -2232.46% | -1894.38% | -3140.08% | -1083.83% |
EBITDA | -12,554 | -13,815 | -7,205 | -5,886 | -6,052 | -5,839 |
D&A For EBITDA | 418.58 | 455.64 | 491.22 | 533.31 | 417.36 | 245.49 |
EBIT | -12,973 | -14,271 | -7,696 | -6,419 | -6,469 | -6,085 |